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Organophosphate (OP) causes phosphorylation of acetylcholinesterase enzyme which leads to accumulation of 
acetylcholine. This phosphorylation generally occurs due to exposure of nerve agents and intake of pesticides, etc. Various 
standard drugs specifically oxime derivatives (HI-6, Obidoxime, 2-PAM, etc.) are used as AChE enzyme reactivation 
agents. These standard drugs show least penetration to CNS. Taking them into consideration with the help of structure and 
ligand based screened compounds, various small molecules analogues targeting CNS have been designed. These analogues 
pass all the pharmacokinetic parameters structurally and have also shown better results than that of standards. Among 
various charged and uncharged analogues, 4g, 4h and 4j have attained docking scores –13.11, –12.84 and –12.75Kcal/mol 
respectively which is better than that of the standard (HI-6) –12.13kcal/mol. 
Keywords: Ligand based drug design, structure based drug design, LOPAC database, virtual screening, docking, analogue 
designing, pharmacokinetic parameters 
Acetylcholinesterase enzyme is responsible for 
acetylcholine degradation which further terminates 
neural transmission1. AChE have mainly two sites i.e., 
active and peripheral. Active site includes residue 
(Ser203, His447, and Glu334) and peripheral sites 
(aromatic residues Tyr72, Tyr124, Trp286, and Tyr341 
and acidic Asp74). These sites responsible for binding 
inhibitors, etc2. AChE enzyme is being blocked or 
phosphorylated sue to presence of phosphate group in 
organophosphate containing compounds (nerve agents, 
pesticides, etc)1. Due to phosphorylation toxicity may 
occur which leads to death further. Covalent bond 
formation occurs between hydroxyl group of Ser203 
residue and phosphorus atom of organophosphate 
which leads to irreversible inhibition at Ser203 residue3. 
Various oxime derivatives are used for the above 
treatment. These derivatives have poor penetration in 
CNS. In this research paper with the help of ligand 
based drug design and structure based drug design 
analogues designing was planned. In ligand based 
drug design with the help of oxime derivatives 
pharmacophore was generated whereas in structure 
based drug design with the help of 2WHP enzyme 
pharmacophore was generated. Once pharmacophore 
were generated by both methods, then LOPAC database 
was screened and with the help of potential leads 
analogue designing was performed targeting CNS4. 
Methodology 
With the help of structure and ligand based 
pharmacophore, screening of LOPAC database was 
done. Essential leads were taken into consideration and 
analogue designing was processed. For docking three 
dimensional target enzyme 2WHP (PDB ID: 2WHP) 
was downloaded from RCSB. It is crystal structure 
of acetylcholinesterase enzyme which is being 
phosphonylated by sarin and in complex with HI-6. 
Design of Analogues 
PharmacoPredicta flagship module of Inventus 
software which has ability to predict relevant 
pharmacokinetic and ADME properties of selected 
Hits/Lead molecules before proceeding ahead with 
cell line and animal studies5,6. This is particularly 
useful when physiology is not known. With the help 
of this module designed analogues targeting CNS 
were being run through it. Structure model was being 
carried with this module. Data has being analysed 
further. 
Results and Discussion 
Analogues Designing 
The principle of analogues designing is analogues 
possessing only chemical similarities7. Total 104 
analogues (charged and uncharged) were being 




designed according to screened and potential leads 
which are obtained through structure based drug 
design and ligand based drug design including 
molecular factors which influence BBB transport, 
enhanced flux across the BBB (and thus improved 
efficacy). This could be attained by designing a 
reactivator with a short carbon linker (C1–C2) in  
the absence of additional functional groups, mono 
quaternary as bisquaternary AChE reactivators have a 
relatively low predicted permeability value (range 
0.538–1.780) which indicates that these compounds 
may be poorly absorbed across the BBB and preferably 
with one or two oxime groups in the para position8. 
The nucleus of the analogues was based on the 
molecular factors mentioned above and the lipophilic 
moiety was being added though screened and 
potential leads. As synthesised charged reactivators 
(HI-6, 2-PAM, etc) show less reactivation and results 
to toxicity, to overcome with this, an attempt is being 
made by designing charged and uncharged analogues 
which can show optimal reactivation with least 
toxicity (Figure 1, Figure 2). As analogues were 
designed for CNS target, out of 104 analogues,  
51 passed blood brain barrier. These analogues are 
presented below in Table I and studied further. 
As lipophilicity was the first of the descriptors to 
be identified as important for CNS penetration. 
However, ClogP correlates nicely with LogBBB with 
increasing lipophilicity increasing brain penetration. 
For several classes of CNS active substances, Hansch 
and Leo found that blood-brain barrier penetration is 
optimal when the LogP values are in the range of  
1.5-2.7, with the mean value of 2.1 9. Considering the 
above range, out of 51 analogues, 15 analogues  
(5 charged and 10 uncharged) were found under 
Lipinski’s rule (Table II). 
Further these analogues were run for structure - 
based algorithms to predict pharmacokinetic properties. 
Although extremely valuable in early drug discovery 
because they require only structural features of the 
compound and not experimental data, these models 
usually correlate compound structures to a dataset for a  
 
 
Figure 1 — Graphical Representation of Charged Analogues Data 






Figure 2 — Graphical Representation of Uncharged Analogues Data 
 
Table I — Analogues structure along with lop P which passed BBB 
Name Structure Log P 
Ana 1a O/N=C\C1=CC=[N+](CC2=CC=C(OC)C=C2)C=C1 2.65 
Ana1b O/N=C\C1=CC=[N+](CNC2CCCCC2)C=C1 2.76 
Ana1c O/N=C\C1=CC=[N+](CC2=CC=C(Cl)C(Cl)=C2)C=C1 3.95 
Ana1d  O/N=C\C1=CC=[N+](CCNC2CCCCC2)C=C1 3.08 
Ana2a O/N=C\C1=CC=[N+](CC2=CC=CC=C2)C=C1 2.64 
Ana2b O/N=C\C1=CC=[N+](CC2CCCCC2)C=C1 3.17 
Ana2c O/N=C\C1=CC=[N+](CC2=CC=C(Cl)C=C2)C=C1 3.29 
Ana2d O/N=C\C1=CC=[N+](C[C@H]2NC3=CC=CC=C3C2)C=C1 2.91 
Ana2e O/N=C\C1=CC=[N+](COC2=CC=CC=C2)C=C1 2.63 
Ana2f O/N=C\C1=CC=[N+](C[C@@H](C2=CC=CC=C2)C3CCCCC3)C=C1 4.96 
Ana2g O/N=C\C1=CC=[N+](CCC2CCCCC2)C=C1 3.56 
Ana2h O/N=C\C1=CC=[N+](CCC(C2)=NC3=C2C=CC=C3)C=C1 3.31 
Ana3a O/N=C\C1=CCN(CC2=CC=C(OC)C=C2)C=C1 2.87 
Ana3b O/N=C\C1=CCN(CNC2CCCCC2)C=C1 2.82 
Ana3c O/N=C\C1=CCN(CC(NC2CCCCC2)=S)C=C1 3.48 
Ana3d O/N=C\C1=CCN(CC2=CC=C(Cl)C(Cl)=C2)C=C1 4.16 
Ana3e O/N=C\C1=CCN(CC2=CC3=CC(Cl)=CC=C3N2)C=C1 3.84 
Ana3f O/N=C\C1=CCN(COC2=CC=CC3=CC=CC=C23)C=C1 3.85 
Ana3g O=C(C(C=C1)=CC=C1F)CN2CC=C(/C=N\O)C=C2 2.96 
Ana3h O/N=C\C1=CCN(CCC2=CC=C(OC)C=C2)C=C1 3.19 
Ana3i O/N=C\C1=CCN(CCNC2CCCCC2)C=C1 3.44 
Ana3j O/N=C\C1=CCN(CCC(NC2CCCCC2)=S)C=C1 3.87 
Ana3k O/N=C\C1=CCN(CCC2=CC=C(Cl)C(Cl)=C2)C=C1 4.49 
Ana3l O/N=C\C1=CCN(CCC2=CC3=CC(Cl)=CC=C3N2)C=C1 4.16 
Ana3m O/N=C\C1=CCN(CCOC2=CC=CC3=CC=CC=C23)C=C1 4.46 
Ana3n O/N=C\C1=CCN(CCC(C(C=C2)=CC=C2F)=O)C=C1 3.35 
Ana4a O/N=C\C1=CCN(CC2=CC=CC=C2)C=C1 2.86 
(Contd.) 




particular pharmacokinetic endpoint, without regard for 
the underlying processes, i.e., physiology10 (Table III). 
 Caco-2 permeability (A→B or apical to basolateral), 
P eff at pH 7.4 (cm/s) 
 Caco-2 permeability (B→A or basolateral to apical) 
at pH 7.4 (cm/s) 
 Efflux at pH 7.4 (0 if ≤ 5.3, 1 if > 5.3) 
 Blood Brain Barrier permeability (0 if no 
penetration, 1 if penetration). 
 Human absorption, FDp (%) results are classified as: 
 Low (0%-33% absorbed) 
 Medium (34%-66% absorbed) 
 High (67%-100% absorbed) 
 Protein Binding (0 if ≤ 85%, 1 if > 85%) 
 Volume of Distribution at Steady State, VDSS (lit.) 
 Prediction Confidence (high, medium, low)5. 
Further refinement of these analogues was done by 
docking. Among these best analogues were obtained  
Table I — Analogues structure along with lop P which passed BBB 
Name Structure Log P 
Ana4b O/N=C\C1=CCN(CC2CCCCC2)C=C1 3.52 
Ana4c O/N=C\C1=CCN(CN)C=C1 0.57 
Ana4d O/N=C\C1=CCN(CC2=CC=C(Cl)C=C2)C=C1 3.51 
Ana4e O/N=C\C1=CCN(CC(N)=S)C=C1 1.23 
Ana4f O/N=C\C1=CCN(CC(C2)CC3=C2C=CC=C3)C=C1 3.36 
Ana4g O/N=C\C1=CCN(C[C@H]2NC3=CC=CC=C3C2)C=C1 3.27 
Ana4h O/N=C\C1=CCN(CC2=CN=CCC2=O)C=C1 1.87 
Ana4i O/N=C\C1=CCN(C[C@@H](O)C2=CC=CC=C2)C=C1 2.68 
Ana4j O/N=C\C1=CCN(CC[C@@H](O)C2CCCCC2)C=C1 3.56 
Ana4k O/N=C\C1=CCN(COC2=CC=CC=C2)C=C1 2.69 
Ana4l O/N=C\C1=CCN(C[C@H](C2CCCCC2)C3=CC=CC=C3)C=C1 5.31 
Ana4m O/N=C\C1=CCN(CC2=CC=C(F)C=C2)C=C1 3 
Ana4n O/N=C\C1=CCN(CCC2=CC=CC=C2)C=C1 3.18 
Ana4o O/N=C\C1=CCN(CCC2CCCCC2)C=C1 3.91 
Ana4p O/N=C\C1=CCN(CCN)C=C1 1.19 
Ana4q O/N=C\C1=CCN(CCC2=CC=C(Cl)C=C2)C=C1 3.84 
Ana4r O/N=C\C1=CCN(CCC(N)=S)C=C1 1.62 
Ana4s O/N=C\C1=CCN(CCC2CC3=CC=CC=C3C2)C=C1 3.75 
Ana4t O/N=C\C1=CCN(CCC2=NC3=CC=CC=C3C2)C=C1 3.66 
Ana4u O/N=C\C1=CCN(CCC2=CN=CCC2=O)C=C1 2.26 
Ana4v O/N=C\C1=CCN(CCC[C@@H](O)C2=CC=CC=C2)C=C1 3.46 
Ana4w O/N=C\C1=CCN(CCOC2=CC=CC=C2)C=C1 3.31 
Ana4x O/N=C\C1=CCN(CCC[C@H](C2CCCCC2)C3=CC=CC=C3)C=C1 6.09 
Ana4y O/N=C\C1=CCN(CCC2=CC=C(F)C=C2)C=C1 3.32 
 
Table II — Under Lipinski’s rule (charged and uncharged analogues) 
Analogues Hydrogen Bond Acceptor Hydrogen Bond Donor Molecular Weight Log P 
Charged Ana 1a 4 1 243.28 2.65 
Ana 1b 4 2 234.32 2.76 
Ana 2a 3 1 213.26 2.64 
Ana 2d 4 2 233.81 2.91 
Ana 2e 4 1 229.25 2.63 
Uncharged Ana 3a 4 1 244.29 2.87 
Ana 3b 4 2 235.33 2.82 
Ana 3d 4 1 260.26 2.96 
Ana 4a 3 1 214.26 2.86 
Ana 4d 4 2 197.26 1.23 
Ana 4g 5 1 231.25 1.87 
Ana 4h 4 2 244.29 2.68 
Ana 4j 4 1 230.26 2.69 
Ana 4n 4 2 211.28 1.62 
Ana 4o 5 1 245.26 2.26 
 





Table III — Structural ADME parameters for charged and uncharged analogues 
Analogues caco74ab caco74ba efflux bbb fdp probind Vdss 
1a 3.65E-05 9.70E-08 0 1 High 0 100 
1b 3.47E-05 5.05E-08 0 1 High 0 100 
2a 4.90E-05 5.29E-07 0 1 High 0 100 
2d 3.40E-05 6.12E-08 0 1 High 0 100 
2e 1.42E-06 6.17E-08 0 1 High 0 100 
3a 4.90E-05 4.60E-05 0 1 High 0 100 
3b 3.47E-05 2.35E-05 1 1 High 0 100 
3d 4.78E-05 4.22E-05 1 1 High 0 10 
4a 4.90E-05 5.22E-05 0 1 High 0 100 
4d 2.15E-05 1.36E-05 1 1 High 0 10 
4g 4.90E-05 5.73E-05 0 1 High 0 1 
4h 2.27E-05 3.41E-05 1 1 High 0 10 
4j 4.90E-05 5.73E-05 0 1 High 0 100 
4n 2.14E-05 1.37E-05 1 1 High 0 10 
4o 4.90E-05 5.66E-05 0 1 High 0 1 
Standard 1.87E-06 1.27E-05 1 1 High 0 100 
 
Table IV — Docking of uncharged (4g, 4h, 4j) and charged (2e, 1b, 2d) analogues Standard (HI-6)  
docking score= -12.130KCAL/MOL 
Analogues Glide XP score (Kcal/mol) 
Residues and 2D images 
Ana 4g Docking Score: -13.11 
Pi cation – TYR124, TRP286. 












Table IV — Docking of uncharged (4g, 4h, 4j) and charged (2e, 1b, 2d) analogues Standard (HI-6)  
docking score= -12.130KCAL/MOL 
Analogues Glide XP score (Kcal/mol) 
Residues and 2D images 
Ana 4h Docking Score: -12.84 
Pi cation – TRP286. 
Pi-Pi stacking- TYR341. 
Salt Bridge- TRP286. 
Hydrogen Bond- ASP74, SER298. 
Hydrophobic Bonds- TYR72, LEU76, TYR341, TRP286, VAL288, LEU289, TYR124, PHE299, 






Ana 4j Docking Score: -12.75 
Pi cation – TRP286, TYR124.  
Pi-Pi stacking- TYR341.  
Hydrogen Bond- SER298 
Hydrophobic Bonds- TYR72, TYR124, TYR337, PHE338, TYR341, ILE294, PHE295, PHE297, 










Table IV — Docking of uncharged (4g, 4h, 4j) and charged (2e, 1b, 2d) analogues Standard (HI-6)  
docking score= -12.130KCAL/MOL 
Analogues Glide XP score (Kcal/mol) 






Ana 2e Docking Score: -12.30 
Pi cation – TRP286.  
Pi-Pi stacking- TYR72, TRP286, TRP286, TYR124, TYR341.  
Hydrogen Bond- SER298.  
Hydrophobic Bonds- TYR72, TYR124, TYR337, PHE338, TYR341, ILE294, PHE295, PHE297, 









Table IV — Docking of uncharged (4g, 4h, 4j) and charged (2e, 1b, 2d) analogues Standard (HI-6)  
docking score= -12.130KCAL/MOL 
Analogues Glide XP score (Kcal/mol) 




Ana 1b Docking Score: -12.03 
Pi cation – TYR341, TRP286, TRP286.  
Pi-Pi stacking- TRP286, TRP286, TYR124, TYR72.  
Salt Bridge- ASP74.  
Hydrogen Bond- SER298.  
Hydrophobic Bonds- TYR72, TYR124, TYR337, PHE338, TYR341, ILE294, PHE295, PHE297, 













Table IV — Docking of uncharged (4g, 4h, 4j) and charged (2e, 1b, 2d) analogues Standard (HI-6)  
docking score= -12.130KCAL/MOL 
Analogues Glide XP score (Kcal/mol) 
Residues and 2D images 
Ana 2d Docking Score: -12.01 
Pi cation – TRP286, TRP286, TYR124. 
Pi-Pi stacking- TRP286, TRP286, TYR124, TYR72, TYR341.  
Hydrogen Bond- TYR124.  
Hydrophobic Bonds- TYR72, TYR124, TYR337, PHE338, TYR341, ILE294, PHE295, PHE297, 







by docking scores and interacting residues which are 
being compared with standard. Top three charged and 
uncharged analogues were being screened out and 
considered as potential leads as their docking scores 
are comparable to standard (HI-6,Table IV). 
 
Conclusion 
In this study, through ligand based drug design a 
pharmacophore model was generated with a dataset of 
79 compounds as acetylcholinesterase reactivators in 
order to analyze the essential structural features which 
are required for binding. Later 3D-QSAR model was 
developed with the help of pharmacophore-based 
alignment. The model explains how the three 
dimensional arrangements of various substituent may 
affect the biological activity of the AChE 
reactivators4. With the use of structure based drug 
design most active site of acetylcholinesterase 
enzyme was being detected which is required for 
binding, as active site residues are responsible for 




biological activity. Screening was done through 
structure and ligand based pharmacophore and 
screened leads were further taken for ADME 
screening. Various leads were considered as potential 
leads as they passed CNS parameters. Further 
refinement was done by performing docking studies 
as binding scores and residues were comparable with 
that of standard (HI-6). With this, for analyzing better 
potency these leads can be further taken for wet lab 
testing. With the help of potential leads, analogues 
designing were also performed. Structural ADME 
parameters, docking scores, residue information of 
potent analogues were comparable with that of 
standard (HI-6).  
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